Example: Heart Attack

Search clinical trials for: Gemcitabine

Total 2475 results

NCT04506281

Recruiting

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Conditions: Cholangiocarcinoma, Intrahepatic
NCT04500561

Not yet recruiting

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Conditions: Diffuse Large B Cell Lymphoma
NCT04498689

Recruiting

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Conditions: Metastatic Pancreatic Cancer
NCT04498767

Not yet recruiting

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

Conditions: Rare Oligometastatic Cancers
NCT04491942

Not yet recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Penile Cancer AJCC v8; Stage IIIA Pleural Malignant Mesothelioma AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Penile Cancer AJCC v8; Stage IIIB Pleural Malignant Mesothelioma AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
NCT04493632

Not yet recruiting

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Conditions: Pancreatic Neoplasm; Digestive System Neoplasm; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasm; Digestive System Disease; Pancreatic Diseases; Endocrine System Diseases
NCT04486391

Not yet recruiting

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT04481009

Not yet recruiting

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Conditions: Advanced Solid Tumors
NCT04481204

Not yet recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Conditions: Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8
NCT04480190

Not yet recruiting

Neoadjuvant Therapy in Biliary Adenocarcinoma

Conditions: Cholangiocarcinoma; Biliary Cancer
NCT04480268

Recruiting

PAXG Out in the Country

Conditions: Pancreatic Ductal Adenocarcinoma
NCT04480372

Not yet recruiting

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Conditions: Malignant Pleural Mesothelioma; Non-small Cell Lung Cancer
NCT04472403

Recruiting

Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma

Conditions: Nasopharyngeal Carcinoma; Metastasis; Chemotherapy; Survival
NCT04469556

Not yet recruiting

Pancreatic Adenocarcinoma Signature Stratification for Treatment

Conditions: Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Advanced Pancreatic Cancer
NCT04470076

Not yet recruiting

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Conditions: Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI
NCT04467593

Not yet recruiting

Safety Study of Whole Body Hyperthermia for Advanced Cancer

Conditions: Advanced Cancer; Pancreatic Cancer Metastatic
NCT04464174

Not yet recruiting

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Conditions: Triple Negative Breast Cancer
NCT04458909

Not yet recruiting

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Conditions: Metastatic Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Metastatic Nasopharyngeal Undifferentiated Carcinoma; Nasopharyngeal Nonkeratinizing Carcinoma; Recurrent Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8; Stage IVA Nasopharyngeal Carcinoma AJCC v8; Stage IVB Nasopharyngeal Carcinoma AJCC v8
NCT04453826

Not yet recruiting

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Conditions: Nasopharyngeal Carcinoma; Chemotherapy; Radiotherapy; PD-1 Therapy
NCT04452357

Recruiting

Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer

Conditions: Pancreatic Cancer
NCT04452461

Not yet recruiting

Pancreatic Adenocarcinoma Neoadjuvant Combination Chemotherapy and Stereotactic Body Radiation Therapy Before Surgery

Conditions: Pancreatic Adenocarcinoma
NCT04448522

Recruiting

Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

Conditions: Nasopharyngeal Carcinoma; Radiotherapy; Chemotherapy
NCT04447092

Not yet recruiting

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Conditions: Pancreatic Cancer; Chemotherapy Effect
NCT04447612

Recruiting

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Conditions: Nasopharyngeal Carcinoma
NCT04442022

Not yet recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04432402

Recruiting

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Conditions: Diffuse Large B Cell Lymphoma
NCT04430036

Not yet recruiting

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Conditions: Urinary Bladder Neoplasms
NCT04425070

Not yet recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Conditions: Peripheral T-cell Lymphoma; NK/T-cell Lymphoma
NCT04421469

Not yet recruiting

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Conditions: Nasopharyngeal Carcinoma
NCT04421547

Not yet recruiting

Efficacy of Letrozole in Recurrent Ovarian Cancer

Conditions: Epithelial Ovarian Cancer
NCT04423731

Recruiting

Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

Conditions: Locally Advanced Pancreatic Adenocarcinoma; Chemotherapy Effect; Borderline Resectable Pancreatic Adenocarcinoma; Pancreatectomy
NCT04413734

Recruiting

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Conditions: Intrahepatic Cholangiocarcinoma by AJCC V8 Stage
NCT04414566

Not yet recruiting

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Conditions: Nasopharyngeal Carcinoma
NCT04408638

Not yet recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions: Diffuse Large B-cell Lymphoma
NCT04405375

Recruiting

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type
NCT04405622

Recruiting

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Conditions: Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Carcinoma; Chemotherapy Effect; Immunotherapy
NCT04401709

Not yet recruiting

Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Conditions: Biliary Tract Cancer
NCT04398108

Not yet recruiting

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Conditions: HER2 Positive Metastatic Breast Cancer
NCT04398368

Not yet recruiting

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Conditions: Stage 0a Renal Pelvis and Ureter Cancer AJCC v8; Stage 0a Renal Pelvis Cancer AJCC v8; Stage 0a Ureter Cancer AJCC v8; Stage 0is Renal Pelvis and Ureter Cancer AJCC v8; Stage 0is Renal Pelvis Cancer AJCC v8; Stage 0is Ureter Cancer AJCC v8; Stage I Renal Pelvis and Ureter Cancer AJCC v8; Stage I Renal Pelvis Cancer AJCC v8; Stage I Ureter Cancer AJCC v8; Stage II Renal Pelvis and Ureter Cancer AJCC v8; Stage II Renal Pelvis Cancer AJCC v8; Stage II Ureter Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8
NCT04390763

Not yet recruiting

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
NCT04390399

Recruiting

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Conditions: Pancreatic Cancer
NCT04386746

Recruiting

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Conditions: Urothelial Carcinoma Bladder; Bladder Cancer
NCT04383119

Not yet recruiting

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Conditions: Leiomyosarcoma of Ovary; Soft Tissue Sarcoma
NCT04384484

Not yet recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Conditions: Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
NCT04378023

Recruiting

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Conditions: Unresectable Cholangiocarcinoma
NCT04379739

Recruiting

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Conditions: Non Small Cell Lung Cancer
NCT04377048

Not yet recruiting

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Conditions: Stage IV Pancreatic Cancer
NCT04373928

Recruiting

Personalized Precision Diagnosis and Treatment of Pancreatic Cancer

Conditions: Pancreatic Cancer
NCT04371224

Recruiting

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Conditions: Pancreatic Cancer; Gemcitabine-pretreated; NaliCap (Nal-IRI/Capecitabine); NAPOLI (Nal-IRI/5-FU/LV)
NCT04365036

Recruiting

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Conditions: NK/T Cell Lymphoma Nos